Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Systemic Review Underscores Need for Smoking Status Data on Genitourinary Cancer Trials

September 13th 2021

Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.

NEJM Data Underscore DFS Benefit With Adjuvant Pembrolizumab in Post-Nephrectomy RCC

September 7th 2021

Adjuvant treatment with pembrolizumab led to a significant improvement in disease-free survival compared with placebo after nephrectomy in patients with renal cell carcinoma who are at high risk for recurrence, as underscored by data from the pivotal phase 3 KEYNOTE-564 trial.

McKay Filters Through Frontline Treatment Considerations in mRCC

September 6th 2021

Dr. McKay discusses the importance of patient selection in advanced renal cell carcinoma, selecting between available combination regimens, and nuances regarding the timing of treatment in this disease.

Cabozantinib Plus Nivolumab Approved in Japan for Unresectable or Metastatic RCC

August 26th 2021

The Japanese Ministry of Health, Labor, and Welfare has approved the combination of cabozantinib and nivolumab for the treatment of patients with unresectable or metastatic renal cell carcinoma.

Incorporating Treatment Advances Into mRCC Management

August 24th 2021

Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.

Emerging Therapies for Relapsed/Refractory mRCC

August 24th 2021

Novel strategies being explored in various stages of clinical trials as potential therapies for relapsed/refractory metastatic renal cell carcinoma.

Dr. Hammers on the Safety Profile of Lenvatinib/Pembrolizumab in RCC

August 20th 2021

Hans Hammers, MD, PhD,discusses the safety profile of lenvatinib in combination with pembrolizumab in renal cell carcinoma.

FDA Approves Adjuvant Nivolumab for High-Risk Urothelial Carcinoma

August 20th 2021

The FDA has approved nivolumab for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection, irrespective of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.

Relapsed/Refractory mRCC: Sequencing Therapy

August 17th 2021

Considerations for how to approach a patient with metastatic renal cell carcinoma previously treated with ipilimumab and nivolumab, followed by nivolumab maintenance.

Treatment Approaches for Relapsed/Refractory mRCC

August 17th 2021

An overview of treatment options for previously treated metastatic renal cell carcinoma.

FDA Issues a Complete Response Letter for Vicineum for High-Risk, BCG-Unresponsive NMIBC

August 16th 2021

The FDA has issued a complete response letter to Sesen Bio regarding its biologics license application for Vicineum for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

Tagawa Takes Stock of Future of Sacituzumab Govitecan in Urothelial Carcinoma

August 16th 2021

Sacituzumab govitecan-hziy, a Trop-2directed antibody-drug conjugate with an SN-38 payload, has carved out a role in the treatment landscape for patients with locally advanced or metastatic urothelial cancer following accelerated approval by the FDA.

FDA Approves Belzutifan for Cancers Linked With Von Hippel-Lindau Disease

August 13th 2021

The FDA has approved belzutifan for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors that do not require immediate surgery.

Neoadjuvant Stereotactic Radiation Shows Early Safety, Feasibility in RCC Inferior Vena Cava Tumor Thrombus

August 12th 2021

Neoadjuvant stereotactic radiation followed by radical nephrectomy and thrombectomy is a safe and feasible treatment option for patients with renal cell carcinoma and inferior vena cava tumor thrombus.

FDA Approves Pembrolizumab Plus Lenvatinib for Frontline Advanced RCC

August 11th 2021

The FDA has approved pembrolizumab plus lenvatinib for the frontline treatment of adult patients with advanced renal cell carcinoma.

FDA Grants Priority Review to Adjuvant Pembrolizumab for Post-Nephrectomy RCC

August 10th 2021

The FDA has granted priority review to a new supplemental biologics license application for pembrolizumab as an adjuvant treatment in patients with renal cell carcinoma.

Adjuvant Therapy Approaches for Operable RCC

August 10th 2021

A summary of current therapies and ongoing investigations of adjuvant therapy for patients with operable renal cell carcinoma.

Therapies Under Investigation for Frontline mRCC

August 10th 2021

Novel therapies currently being investigated as frontline options for metastatic renal cell carcinoma.

Checkpoint Inhibitor/TKI Combos Jump RCC Treatment to Next Level

August 9th 2021

Five-year survival rates in renal cell carcinoma are drastically improving due to recent regulatory approvals of combination therapies involving checkpoint blockade and VEGF TKIs.

Pembrolizumab/Lenvatinib Under Evaluation in Frontline Non–Clear Cell RCC

August 4th 2021

Chung-Han Lee, MD, PhD, discusses the goals of the phase 3 KEYNOTE-B61 study and the potential for immunotherapy/TKI combinations in non–clear cell RCC.